share_log

Arcutis Biotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

Arcutis Biotherapeutics | 144:擬議出售證券

SEC announcement ·  03/04 17:54
Moomoo AI 已提取核心訊息
Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe is set to sell 14,903 shares of common stock on 03/04/2024, with an aggregate market value of $165,739. The shares to be sold were recently acquired through restricted stock vesting on 03/01/2024 and 03/03/2024, totaling 14,903 shares. This transaction follows a recent sale of 2,465 shares by Watanabe on 02/28/2024, which grossed $26,129.
Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe is set to sell 14,903 shares of common stock on 03/04/2024, with an aggregate market value of $165,739. The shares to be sold were recently acquired through restricted stock vesting on 03/01/2024 and 03/03/2024, totaling 14,903 shares. This transaction follows a recent sale of 2,465 shares by Watanabe on 02/28/2024, which grossed $26,129.
Arcutis Biotherapeutics, Inc.高管渡邊託德·富蘭克林定於2024年4月3日出售14,903股普通股,總市值爲165,739美元。擬出售的股票最近於2024年1月3日和2024年3月3日通過限制性股票歸屬收購,共計14,903股。該交易是在渡邊最近於2024年2月28日出售了2465股股票之後進行的,總收入爲26,129美元。
Arcutis Biotherapeutics, Inc.高管渡邊託德·富蘭克林定於2024年4月3日出售14,903股普通股,總市值爲165,739美元。擬出售的股票最近於2024年1月3日和2024年3月3日通過限制性股票歸屬收購,共計14,903股。該交易是在渡邊最近於2024年2月28日出售了2465股股票之後進行的,總收入爲26,129美元。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息